Who is sponsoring NCT05939089?

NCT05939089 is sponsored by Istanbul University.

What drugs are being tested in NCT05939089?

Interventions in NCT05939089: ECG, Echocardiography, cTnI, NT-ProBNP.

What condition does NCT05939089 study?

NCT05939089 studies Left Ventricular Dysfunction, Heart Failure.

Is NCT05939089 still recruiting?

NCT05939089 is currently completed. Last updated 11 July 2023.

Last reviewed 2023-07-11 · How we verify

NCT05939089: CASPER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cardiovascular Assessment of Pediatric Cancer Survivors

Completed Last updated 11 July 2023

What this trial tests

trial testing ECG, Echocardiography, cTnI, NT-ProBNP in Left Ventricular Dysfunction in 54 participants. Completed in 22 June 2023.

Timeline

1 January 2023

Primary endpoint
15 June 2023

22 June 2023

Quick facts

Lead sponsor	Istanbul University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	54
Start date	1 January 2023
Primary completion	15 June 2023
Estimated completion	22 June 2023
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

ECG, Echocardiography, cTnI, NT-ProBNP

Conditions studied

Left Ventricular Dysfunction — all drugs for Left Ventricular Dysfunction →
Heart Failure — all drugs for Heart Failure →

Sponsor

Istanbul University

Who can join

18 and older, any sex, with Left Ventricular Dysfunction or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to evaluate cardiac and vascular health status of pediatric cancer survivors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Left Ventricular Dysfunction

Currently open trials in the same condition.

NCT05760924 — Left Bundle Branch Pacing on Outcomes and Ventricular Remodeling in Biventricular CRT Nonresponders · NA · recruiting
NCT06356727 — Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling · NA · recruiting
NCT05769036 — Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients · NA · recruiting
NCT05989945 — HIDRAdenitis Suppurativa and HEART Disease · active not recruiting
NCT05764057 — DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction · Phase 3 · recruiting

Other Istanbul University trials

Trials by the same sponsor.

NCT07472946 — Whole-Body Vibration Exercise in Patients With Parkinson's Disease · NA · not yet recruiting
NCT07433894 — Scoliosis and Functional Outcomes in Children With Juvenile Idiopathic Arthritis · not yet recruiting
NCT07420049 — Turkish Adaptation of the CTS-6 Evaluation Tool: A Validation and Reliability Study · not yet recruiting
NCT07415967 — The Effect of a Dual-Task Technique-Based Exercise Program on Clinical Outcomes in Rotator Cuff Related Shoulder Pain · NA · recruiting
NCT07473024 — pEEG-Guided Anesthesia and Behavioral Outcomes in Children · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05939089 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istanbul University
Last refreshed: 11 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05939089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing